Press releases
- Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch
- Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response
- Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting
- Precigen Reports First Quarter 2024 Financial Results and Business Updates
- Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting
More ▼
Key statistics
As of last trade Precigen Inc (I5X:DUS) traded at 1.48, -13.16% below its 52-week high of 1.70, set on Jul 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.48 |
---|---|
High | 1.48 |
Low | 1.48 |
Bid | 1.51 |
Offer | 1.57 |
Previous close | 1.49 |
Average volume | 0.00 |
---|---|
Shares outstanding | 252.42m |
Free float | 223.42m |
P/E (TTM) | -- |
Market cap | 416.49m USD |
EPS (TTM) | -0.3896 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 11:30 BST.
More ▼